У нас вы можете посмотреть бесплатно Advancements in Myeloma | What progress towards a cure and prevention has been made? или скачать в максимальном доступном качестве, которое было загружено на ютуб. Для скачивания выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса savevideohd.ru
In this week's #AskDrDurie, myeloma expert Dr. Brian G.M. Durie answers the question:Are we getting closer to a myeloma cure or finding ways to prevent this disease? Dr. Durie discusses the latest advancements in myeloma treatment and prevention from the International Myeloma Foundation's Black Swan Research initiative. Learn about some of the IMF's promising cure trials, the importance of MRD-negativity, and strategies for early detection and prevention. The BOTTOM LINE: Significant advancements by the IMF have been made in both the pursuit of a cure for myeloma and strategies for prevention, bringing hope for improved outcomes and quality of life for patients. _______________ Improving Lives | Finding the Cure Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy. Subscribe to our channel: / imfmyeloma Visit our website at: https://www.myeloma.org Find us online: Facebook: @myeloma | / myeloma Twitter: @IMFMyeloma | / imfmyeloma Instagram: @imfmyeloma | / imfmyeloma LinkedIn: / international-myeloma-foundation Support the IMF | Donate Now! https://fundraise.myeloma.org/give/52... Category Nonprofits & Activism License Standard YouTube License In most cases, captions are autogenerated by YouTube.